



Efficacy and Adverse Event Profile of the iStent and iStent Inject Trabecular Micro-bypass for Open-angle Glaucoma: A Meta-analysis

¹Marko Popovic, ²Xavier Campos-Möller, ³Hady Saheb, ⁴Iqbal Ike K Ahmed

ABSTRACT

Aim: This meta-analysis explores the efficacy and adverse event profile of the iStent, an ab interno implant for the treatment of open-angle glaucoma.

Methods: A systematic literature search of Ovid MEDLINE and EMBASE was used to identify peer-reviewed original studies that provided efficacy data on the first or second generation iStent for at least five eyes. Intraocular pressure (IOP) was the primary efficacy endpoint, while the number of medication classes was the secondary outcome. Weighted mean differences were reported for continuous endpoints, while a relative risk was computed for dichotomous variables.

Review Results: The search revealed 545 results, of which 1767 eyes from 28 studies were included. The cohort age was 71.4 ± 5.4 years, and 44.9% of patients were male. There was a significantly greater IOP reduction after the use of two first-generation stents compared to one, irrespective of phacoemulsification status ($p < 0.001$). Additionally, there was a significantly greater IOP reduction following iStent alone relative to phaco-iStent for the first-generation iStent ($p < 0.001$) and the iStent inject ($p < 0.001$). For the first generation stent, combined phaco-iStent provided a greater level of IOP reduction ($p < 0.001$) and reduction in the number of medication classes relative to phacoemulsification alone ($p < 0.001$). In total, 22.5% of eyes that received iStent implantation sustained some type of adverse event. The most common adverse events were intraocular pressure elevation, stent blockage or obstruction, stent malposition and hyphema.

Conclusion and Clinical Significance: Statistically significant differences in efficacy outcomes exist between different numbers of stents and the presence or absence of concurrent phacoemulsification.

Keywords: Clinical efficacy, Glaucoma, Meta-analysis, Surgical instruments,

How to cite this article: Popovic M, Campos-Möller X, Saheb H, Ahmed IK. Efficacy and Adverse Event Profile of the iStent and iStent Inject Trabecular Micro-bypass for Open-angle Glaucoma: A Meta-analysis. *J Curr Glaucoma Pract* 2018;12(2):67-84.

Source of support: Nil

Conflict of interest: Consultant to Glaukos and Allergan.

BACKGROUND

Given the irreversible retinal ganglion cell damage resulting from open-angle glaucoma (OAG), current treatment modalities are focused on preserving the structural integrity of the optic nerve and visual function.¹⁻³ Prospective evaluations in glaucoma have demonstrated that the reduction of IOP leads to significant sparing of vision: namely, every 1 mm Hg reduction of IOP is correlated with an approximate 10% decrease in the risk of glaucomatous progression.⁴

In OAG, IOP elevation is often a result of reduced aqueous humor flow through the trabecular meshwork⁵ In early stages, ocular hypotensive medications and laser trabeculoplasty have been shown to attenuate glaucoma progression; however there are well known issues with compliance, tolerability, persistence, and difficulty of proper instillation.^{3,5} In the situations in which these treatments are insufficient in reducing IOP to target pressures according to disease severity, ab externo filtering procedures are utilized to provide a more significant IOP reduction. Unfortunately, these techniques are higher risk options that may result in a bleb-related complication, hemorrhage, hyphema, hypotony, infection, inflammation, loss of vision or reoperation.^{6,7}

Recently, there has been increasing interest in the ability of microinvasive glaucoma surgery (MIGS) devices to provide a significant level of IOP reduction with less severe postoperative adverse events.⁸ One such device, the iStent® (Glaukos Corporation, San Clemente, California), is the first ab interno glaucoma implant that has been approved for the management of mild-to-moderate OAG.⁹ The iStent works by allowing aqueous humor to drain directly from the anterior chamber into Schlemm's canal, thus bypassing a portion of the trabecular meshwork and reducing IOP.¹⁰ Currently, the iStent has only received

¹Research Assistant, ²⁻⁴Ophthalmologist

¹Faculty of Medicine, University of Toronto, Toronto, Canada

²Western Health Eye Care Centre, Corner Brook, Newfoundland, Canada

³Department of Ophthalmology, McGill University, Montreal, Quebec, Canada

⁴Department of Ophthalmology and Vision Sciences, University of Toronto, Mississauga, Ontario, Canada

Corresponding Authors: Iqbal Ike K Ahmed, Ophthalmologist, Department of Ophthalmology and Vision Sciences, University of Toronto, Mississauga, Ontario, Canada, Phone: 9054563937, e-mail: ike.ahmed@utoronto.ca

food and drug administration approval for use combined with cataract surgery.

Multiple randomized controlled trials and case series have investigated the efficacy and adverse event profile of the iStent device.^{2,11-37} Some have directly compared the combination of iStent implantation and phacoemulsification to phacoemulsification alone.^{3,16,17,19-22,30} Others have been single-armed case series or have compared the iStent to ocular hypotensive medications.^{11-15,18,23-29} More recent research has focused on a second-generation trabecular micro-bypass device termed the iStent inject,^{11,14,20,24,29,34,36} which consists of two heparin coated titanium stents that are both inserted ab interno through the trabecular meshwork into Schlemm's canal.²⁹ Differences in outcomes between single versus multiple iStents have also been investigated.^{11,13,14,17,20,21,23-25,29,31} In general, most studies have focused on patients with early stages of primary OAG.^{11,14-16,21,22,27-29,32}

There has been a rapid expansion of iStent research in recent years.^{3,11-37} Given these new data, it is uncertain whether there are any differences in efficacy between single versus multiple stents or between phaco-iStent compared to either iStent alone or phacoemulsification alone. Additionally, the most frequently reported adverse events in the literature following iStent therapy should be identified. As such, the following meta-analysis aims to investigate the efficacy and adverse event profile of iStent implantation for the management of OAG.

METHODS

Literature Search and Data Collection

A systematic literature search was performed on Ovid MEDLINE (2006–Week 1 2018) and Ovid EMBASE (2006–2018 Week 3). The search strategy that was used can be found in Table 1A and B. Further, Google, Google Scholar and the reference lists of past reviews were manually searched to elicit further relevant literature. Any original prospective or retrospective clinical study that provided relevant efficacy data (i.e., IOP and number of medication classes) on the implantation of the iStent for at least five eyes was included. Only peer-reviewed journal articles were included. Non-english studies, letters to the editor, correspondences, editorials, reviews, opinions, case reports, articles reporting on other surgical procedures and studies that contained repeat data or less than 4 week follow-up were excluded. Studies were screened first by consulting titles and abstracts and afterwards by examining full-text versions. To assist with the screening process, a quality assessment of articles was performed. The Cochrane criteria were used in the assessment of

Table 1A: Search strategy for Ovid MEDLINE

#	Searches	Results
1	iStent.m_titl.	29
2	iStent.mp.	62
3	Trabecular micro-bypass.mp.	25
4	Glaukos.mp.	30
5	Microinvasive glaucoma surgery.mp.	12
6	Minimally invasive glaucoma surgery.mp.	38
7	Minimally Invasive Surgical Procedures/	24740
8	Ophthalmologic Surgical Procedures/	12012
9	7 and 8	86
10	Stents/	65102
11	Glaucoma/	37134
12	10 and 11	43
13	1 or 2 or 3 or 4 or 5 or 6 or 9 or 12	222
14	Limit 13 to yr = "2006-Current"	205

Table 1B: Search strategy for Ovid EMBASE

#	Searches	Results
1	iStent.m_titl.	47
2	iStent.mp.	158
3	Trabecular micro-bypass.mp.	52
4	Glaukos.mp.	125
5	Microinvasive glaucoma surgery.mp.	27
6	Minimally invasive glaucoma surgery.mp.	73
7	Minimally invasive surgery/	33752
8	Eye surgery/	66
9	1 and 8	66
10	Stent/	81559
11	Glaucoma/	51832
12	10 and 11	87
13	1 or 2 or 3 or 4 or 5 or 6 or 9 or 12	358
14	Limit 13 to yr = "2006-Current"	340

randomized controlled trials, while the National Institute for Health and Care Excellence tool was used to evaluate case series.^{38,39} In both cases, studies were excluded if there was a high risk of bias in at least half of the assessment categories.

Variables that were included for the baseline demographic evaluation were country of origin, study design, distribution of right and left eyes, age, gender, ethnicity, cup-to-disc ratio, visual field, mean deviation and time of follow-up. The primary efficacy endpoint, IOP, was collected as a continuous variable (i.e., IOP postoperatively and reduction pre- to post-operatively). The postoperative number of hypotensive medication classes and pre- to post-operative reduction in the number of medication classes was the secondary endpoint. For the efficacy analysis, data on the number of iStents and phacoemulsification status (i.e., whether concomitant phacoemulsification was performed) were extracted. For adverse event analysis, the number of events and the four most prevalent events for each study arm were recorded.

Postoperative outcomes were collected at last follow-up.

Statistical Analysis

Weighted mean differences (WMD) and corresponding 95% confidence intervals (95% CI) were reported in the analysis of primary and secondary endpoints. Throughout the analysis, the number of eyes (i.e., sample size) was used as a weighted variable. Alongside a random effects model, the inverse variance method was used in the meta-analysis. The weighted mean was defined as

$$\bar{x} = \frac{\sum_{i=1}^n w_i x_i}{\sum_{i=1}^n w_i}$$

while the weighted standard deviation was computed using the formula

$$sd_w = \sqrt{\frac{\sum_{i=1}^n w_i (x_i - \bar{x}_w)^2}{(N' - 1) \sum_{i=1}^n w_i}}$$

Due to the differential reporting of included studies, each unique endpoint contains data from a different collection of studies. A consequence of this is that the WMDs of IOP and medication class reduction will likely not equal the difference between the preoperative and postoperative values for IOP and medication class count.

In the test for overall effect, a p-value of less than 0.05 was considered statistically significant. The main analysis was performed based on whether patients had 1, 2 or 3 iStents implanted and whether they did or did not receive combined phacoemulsification and iStent. All statistical analyses were performed using Review Manager (RevMan 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and Microsoft® Excel (Microsoft Corporation, Redmond, Washington).

REVIEW RESULTS

Study Inclusions and Baseline Demographics

The systematic search revealed 545 results. Upon title and abstract screening, the number of potential articles was reduced to 135. Afterwards, full-text screening resulted in 28 studies that met all inclusion criteria (Fig. 1).^{3,11-37}

Baseline characteristics and the results of quality assessment for included studies are reported on Table 2A. Within the cohort of 1773 eyes for which there was relevant demographic information, the mean age was 71.4 ± 5.4 years ($n = 1606$; cohort range: 54.4–78.8 years), and 747 out of 1662 eyes were male (44.9%). Most eyes came from Caucasian patients (870 out of 1089 eyes, 79.9%). Generally, studies were moderate to high quality (Tables 2B and C). No study met the a priori condition for exclusion based on the quality assessment.




Fig. 1: Modified preferred reporting Items for systematic reviews and meta-analysis (PRISMA) flow diagram

Of the 1767 eyes included in the efficacy and adverse event analysis, a total of 1217 (68.9%) underwent combined iStent implantation and phacoemulsification, while 497 eyes (28.1%) underwent iStent implantation alone (Table 3). More than half of included eyes had one iStent implanted (999, 56.5%), while 685 eyes had two (38.8%) and 63 eyes received three (3.6%). Overall, the vast majority of eyes (1398, 79.1%) received a first generation iStent, while only 369 eyes (20.9%) received an iStent inject. The distribution of relevant clinical features between groups is presented in Table 4.

In terms of study design, the majority (19/28; 67.9%) of studies were case series, while another 17.9% (5/28) were randomized controlled trials. A total of 60.7% of studies were prospective (17/28), while the rest (11/28, 39.3%) were retrospective. Most studies (22/27; 81.5%) extracted data from a single center while a smaller number were multicentered (5/27; 18.5%).

Number of iStents—First Generation

Not accounting for phacoemulsification status, meta-analysis was only possible to evaluate the effect of the number of stents on IOP and medication class reduction for first generation iStents (Table 5A-C, Figs 2A and B). When examining IOP reduction, there was a significantly greater decrease after two stents compared to one [WMD = -1.36 mm Hg, 95% CI = (-1.92 mm Hg, -0.80 mm Hg), $p < 0.001$]. This may have been influenced by the fact that two-stent patients had a significantly greater preoperative IOP than one-stent patients [WMD = -1.35 mm Hg, 95% CI = (-1.85 mm Hg, -0.85 mm Hg), $p < 0.001$]. At the same time, implantation of two stents led to a lesser postoperative IOP when compared to one [WMD = 1.02 mm Hg, 95% CI = (0.80 mm Hg, 1.24 mm Hg), $p < 0.001$]. There was a greater IOP reduction [WMD = -4.66 mm Hg, 95% CI = (-6.20 mm Hg, -3.12 mm Hg), $p < 0.001$], higher

Table 2A: Baseline demographics of included trials

Study	Country	Single center or multicenter	Study design	2016 journal 2-year cites per document	Number of eyes	Age	Number of males	Number of caucasi-ans	Mean cup-to-disk ratio	Mean visual field (MD, dB)
Samuelson et al., 2011	United States	Multicenter	Prospective randomized controlled trial	Ophthalmology; 7.40	117	74 ± 8	46	83	n/a	-3.75 ± 3.03
Fea et al., 2014	Europe	Multicenter	Prospective randomized controlled trial	Clinical ophthalmology; 1.86	94	64.5 ± 10.3	37	94	n/a	n/a
Buchacra et al., 2011	Spain	Single center	Prospective case series	Clinical ophthalmology; 1.86	10	54.4 ± 7.9	9	n/a	n/a	n/a
Ahmed et al., 2014	Armenia	Single center	Prospective case series	Journal of Cataract and Refractive Surgery; 2.69	39	62.8 ± 12.6	21	39	0.7 ± 0.1	-6.47 ± 7.2
Voskanyan et al., 2014	Europe	Multicenter	Prospective case series	Advances in therapy; 2.98	99	66.4 ± 10.9	43	95	0.7 ± 0.2	n/a
Vandewalle et al., 2009	Belgium	Single center	Prospective case series	Bulletin de la Societe Belge d'Ophthalmologie; 0.158 (2015)	10	69	n/a	n/a	n/a	-13.7
Fea, 2010	Italy	Single center	Prospective randomized controlled trial	Journal of Cataract and Refractive Surgery; 2.69	12	64.5 ± 3.4	4	n/a	n/a	n/a
Belovay et al., 2012	Canada	Single center	Prospective case series	Journal of Cataract and Refractive Surgery; 2.69	26	78.8 ± 7	7	18	0.76 ± 0.16	-12.6 ± 7.1
2nd study arm	Canada	Single center	Prospective case series	Journal of Cataract and Refractive Surgery; 2.69	23	75 ± 7.3	9	11	0.71 ± 0.17	-10.2 ± 8.1
Patel et al., 2013	United Kingdom	Single center	Prospective case series	Clinical and Experimental Ophthalmology; 2.93	44	76.8	n/a	n/a	n/a	n/a
Arriola-Villalobos et al., 2012)	Spain	Single center	Prospective case series	British Journal of Ophthalmology; 3.52	19	74.63 ± 8.44	9	19	n/a	n/a
Arriola-Villalobos et al., 2013	Spain	Single center	Prospective case series	British Journal of Ophthalmology; 3.52	20	75.1 ± 8.6	9	20	n/a	n/a
Fernandez-Barrientos et al., 2010	Spain	Single center	Prospective randomized controlled trial	Investigative Ophthalmology and Visual Science; 3.15	17	75.2 ± 7.2	6	n/a	n/a	n/a
Spiegel et al., 2009	Europe	Multicenter	Prospective case series	European Journal of Ophthalmology; 1.15	47	76.2 ± 6.7	18	46	n/a	n/a
Wang et al., 2015	Canada	Single center	Retrospective case series	Journal of Ophthalmology; 1.79	96	70.6 ± 2.8	53	86	n/a	-7.3 ± 2.1
Klamann et al., 2015	Germany	Single center	Retrospective case series	Graefe's Archive for Clinical and Experimental Ophthalmology; 2.42	35	61.3 ± 3.5	15	n/a	n/a	n/a
Khan et al., 2015	Canada and United States	Multicenter	Retrospective case series	Journal of Cataract and Refractive Surgery; 2.69	49	77.5 ± 11.9	20	34	n/a	-11.5 ± 8.0

Contd...

Contd...

Study	Country	Single center or multicenter	Study design	2016 journal per document	Number of eyes	Age	Number of males	Number of caucasi-ans	Mean cup-to-disk ratio	Mean visual field (MD, dB)
Seibold et al., 2016	United States	Single center	Retrospective case series	Journal of Cataract and Refractive Surgery; 2.69	64	73.9 ± 8.8	23	34	n/a	n/a
Gallardo et al., 2016	United States	Single center	Retrospective case series	Clinical Ophthalmology; 1.86	100	74.6 ± 8.9	37	14	0.7 ± 0.2	n/a
Ferguson et al., 2016	United States	Single center	Retrospective case series	Clinical Ophthalmology; 1.86	350	74.1 ± 9.0	133	n/a	n/a	n/a
Lindstrom et al., 2016	Armenia	Single center	Prospective case series	Advances in Therapy; 2.98	57	65.3 ± 9.0	30	57	0.7 ± 0.1	-4.9 ± 5.3
Ei Wardani et al., 2015	Switzerland	n/a	Retrospective case series	Klinische Monatsblätter für Augenheilkunde; 0.52	31	n/a	n/a	n/a	n/a	n/a
2nd Study Arm	Switzerland	n/a	Retrospective case series	Klinische Monatsblätter für Augenheilkunde; 0.52	22	n/a	n/a	n/a	n/a	n/a
Katz et al., 2015	Armenia	Single center	Prospective randomized controlled trial	Clinical Ophthalmology; 1.86	38	68.1 ± 9.1	27	38	0.68 ± 0.11	-4.72 ± 4.42
2nd Study Arm	Armenia	Single center	Prospective randomized controlled trial	Clinical Ophthalmology; 1.86	41	67.8 ± 9.3	19	41	0.71 ± 0.14	-5.20 ± 5.65
3rd Study Arm	Armenia	Single center	Prospective randomized controlled trial	Clinical Ophthalmology; 1.86	40	60.9 ± 8.1	19	40	0.70 ± 0.12	-4.81 ± 4.22
Shiba et al., 2017	Japan	Single center	Prospective case series	Journal of Ophthalmology; 1.79	10	64.6 ± 10.7	7	0	n/a	-15.4 ± 8.1
Zheng et al., 2017	USA	Single center	Retrospective case series	International Journal of Ophthalmology; 1.30	34	74	9 of 30	21 of 30	n/a	n/a
Berdahl et al., 2017	Armenia	Single center	Prospective case series	Clinical & Experimental Ophthalmology; 2.93	53	64.7 ± 9.6	27	53	0.7 ± 0.1	n/a
Ferguson et al., 2017	USA	Single center	Retrospective case series	Journal of Cataract and Refractive Surgery; 2.69	115	77.42 ± 8.51	86	n/a	0.68 ± 0.11	n/a
Gonnermann et al., 2017	Germany	Single center	Retrospective case series	Graefe's Archive for Clinical and Experimental Ophthalmology; 2.42	27	73.8 ± 7.8	13	27	n/a	n/a
Kurji et al., 2017	Canada	Single center	Retrospective case series	Canadian Journal of Ophthalmology; 1.57	34	75.02 ± 10.34	11	n/a	n/a	n/a

*MD = Mean deviation; dB = Decibels; n/a = Not available.

Table 2B: Quality assessment of included randomized controlled trials (Cochrane criteria)

Study	Year	Random sequence generation (Selection bias)	Allocation concealment (Selection bias)	Blinding of participants and personnel (Performance bias)	Blinding of outcome assessment (Detection bias)	Incomplete outcome data (Attrition bias)	Selective reporting (Reporting bias)	Other bias
Samuelson et al.	2011	Low	Unclear	High	Low	High	Low	Low
Fea et al.	2014	Unclear	Unclear	High	High	Low	Low	Low
Fea	2010	Low	Unclear	Low	Low	Low	Low	Low
Fernandez-Barrientos et al.	2010	Low	Unclear	Unclear	Low	Low	Low	Low
Katz et al.	2015	Unclear	Unclear	High	High	Low	Low	Low

Table 2C: Quality assessment of included case series (National Institute for Health and Care Excellence Criteria)

Study	Year	Multicentered	Study objective described	Inclusion and exclusion criteria reported	Outcomes definition reported	Prospective	Consecutive recruitment	Description of study findings	Stratification of outcomes
Buchacra et al.	2011	No	Yes	Yes	No	Yes	Unclear	Yes	No
Ahmed et al.	2014	No	Yes	No	Yes	Yes	Unclear	Yes	No
Voskanyan et al.	2014	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No
Vandewalle et al.	2009	No	Yes	Yes	Yes	Yes	Unclear	Yes	No
Belovay et al.	2012	No	Yes	Yes	No	Yes	Unclear	Yes	No
Patel et al.	2013	No	Yes	Yes	No	Yes	Unclear	Yes	No
Arriola- Villalobos et al.	2012	No	Yes	Yes	No	Yes	Unclear	Yes	No
Arriola- Villalobos et al.	2013	No	Yes	Yes	No	Yes	Yes	Yes	No
Spigel et al.	2009	Yes	Yes	Yes	No	Yes	Unclear	Yes	No
Wang et al.	2015	No	Yes	No	Yes	No	Yes	Yes	Yes
Klamann et al.	2015	No	Yes	Yes	Yes	No	Yes	Yes	No
Khan et al.	2015	Yes	Yes	Yes	No	No	Unclear	Yes	Yes
Seibold et al.	2016	No	Yes	Yes	Yes	No	Unclear	Yes	No
Gallardo et al.	2016	No	Yes	Yes	Yes	No	Yes	Yes	Yes
Ferguson et al.	2016	No	Yes	Yes	Yes	No	Yes	Yes	Yes
Lindstrom et al.	2016	No	Yes	Yes	Yes	Yes	Unclear	Yes	No
El Wardani et al.	2015	No	Yes	Yes	Yes	No	Yes	Yes	Yes
Shiba et al.	2017	No	Yes	Yes	Yes	Yes	Yes	Yes	No
Zheng et al.	2017	No	Yes	Yes	No	No	Unclear	Yes	No
Berdahl et al.	2017	No	Yes	Yes	Yes	Yes	Unclear	Yes	No
Ferguson et al.	2017	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Gonnermann et al.	2017	No	Yes	Yes	Yes	No	Unclear	Yes	No
Kurji et al.	2017	No	Yes	Yes	Yes	No	Yes	Yes	Yes




Fig. 2A: Number of first generation iStents–IOP




Fig. 2B: Number of First Generation iStents–number of medication classes



Efficacy and Adverse Event Profile of the iStent and iStent Inject Trabecular Micro-Bypass for Open-Angle Glaucoma

Table 3: Efficacy endpoints and stratification characteristics of included trials

Study	Number of Eyes	IOP reduction	IOP Preoperatively	IOP Postoperatively	Reduction in medications	Number of Medications		Follow-up (months)	Number of iStents	Combined Phacoemulsification	iStent Generation	Type of Glaucoma
						Preoperatively	Postoperatively					
Samuelson et al., 2011	117	8.4± 3.6	25.2 ±3.5	n/a	1.4±0.8	1.5 ±0.7	0.2±0.6	12	1	Yes	First	Any
Fea et al., 2014	94	12.2± 2.5	25.2 ±1.4	13.0±2.3	n/a	1.0±0	n/a	12	2	No	Second	Primary
Buchacra et al., 2011	8	6.6±5.4	26.5± 7.9	17.0±2.5	1.1±0.6	2.9±0.7	2	12	1	No	First	Secondary
Ahmed et al., 2014	39	13.5	25.3 ±1.8	11.8±2.1	1.0±0	2.0±0	1.0±0	18	2	No	First	Any
Voskanyan et al., 2014	88	10.4±3.2	26.3± 3.5	15.7±3.7	n/a	2.21±0.44	n/a	12	2	No	Second	Pseudoexfoliative
Vandewalle et al., 2009	9	4.2	20	15.8	1	2.7	1.7	12	1	Mixed	First	Primary
Fea, 2010	12	3.2±3	17.9± 2.6	14.8±1.2	1.6	2±0.9	0.4±0.7	15	1	Yes	First	Primary
Belovay et al., 2012	28	3.5	17.3±4	13.8±4	1.8	2.8±0.8	1.0±1.1	12	2	Yes	First	Primary, mixed
2nd study arm	25	3.9	18.6±4	14.8±3	2.2	2.6±1.2	0.4±0.5	12	3	Yes	First	Primary, mixed
Patel et al., 2013	44	5	21.5 ±5	16.5±3	1.7	2.3±0.9	0.6±1.0	6	1	Mixed	First	Any
Arriola Villalobos et al., 2012	19	3.16±3.9	19.42±1.89	16.26±4.23	0.47±0.96	1.32±0.48	0.84±0.89	Mean: 53.68±9.26	1	Yes	First	Any
Arriola-Villalobos et al., 2013	20	9.42±3	26±3.11	16.75±2.24	1±0.79	1.3±0.66	0.3±0.57	12	1 or 2	Yes	Second	Any open angle
Fernandez-Barrientos et al., 2010	17	6.6±3.0	24.2±1.8	17.6±2.8	1.1	1.1±0.5	0	12	2	Yes	First	Primary
Spiegel et al., 2009	42	4.4±4.54	21.7±3.98	17.4±2.99	1.2±0.7	1.6±0.8	0.4±0.62	12	1	Yes	First	Primary
Wang et al., 2015	96	2.50±5.80	n/a	n/a	1.38±1.43	2.14±0.16	0.76	3	2	Yes	First	Any
Klamann et al., 2015	32	7.67	22.39±1.81	14.72±0.80	1.3	2.26±0.1	0.96±0.11	6	2	No	Second	Primary, pseudoexfoliative, pigmentary
Khan et al., 2015	49	n/a	19.6±5.2	14.3±3.1	n/a	2.86±0.91	1.22±1.28	12	2	Yes	First	Primary, pseudoexfoliative, pigmentary
Seibold et al., 2016	64	1.5	14.7±3.2	13.2±2.8	0.4	1.8±1.1	1.4±1.5	12	1	Yes	First	Any
Gallardo et al., 2016	134	3.6	16.5±3.7	12.9±2.1	1.4	2.3±1.1	0.9±1.2	12	1	Yes	First	Primary
Ferguson et al., 2016	350	4.0	19.1±6.3	15.2±3.5	0.6	1.2±1.0	0.6±1.0	24	1	Yes	First	Primary
Lindstrom et al., 2016	57	10.0	24.4±1.3	14.4±2.1	1.0	1.0±0	0.02	18	2	No	Second	Primary
El Wardani et al., 2015	31	1.6	16.7	15.1	1.7	2.5	0.8	6	1	Yes	First	N/a
2nd Study Arm	22	3.2	17	13.8	1.1	2.1	1	6	2	Yes	First	N/a
Katz et al., 2015	37	10.6	25.0±1.1	14.4 ±1.2	1.6	1.71± 0.61	0.11	12	1	No	First	Primary, pseudoexfoliative, pigmentary
2nd study arm	41	12.2	25.0±1.7	12.8 ±1.4	1.66	1.76±0.54	0.10	12	2	No	First	Primary, pseudoexfoliative, pigmentary

Contd...

Contd...

Study	Number of Eyes	IOP reduction	IOP Preoperatively	IOP Postoperatively	Reduction in medications	Number of Medications		Follow-up (months)	Number Combined of iStents	Phacoemulsification	iStent Generation	Type of Glaucoma
						Preoperatively	Postoperatively					
3rd study arm	38	12.9	25.1±1.9	12.2 ±1.5	1.43	1.51± 0.69	0.08	12	3	No	First	Primary, pseudoexfoliative, pigmentary
Shiba et al., 2017	10	5.1	22.0±3.0	16.9 ±3.6	0	3± 0	3±0	6	2	No	First	Primary
Zheng et al., 2017	17	3	19.7±4.1	16.7 ±2.1	1.4	2.2± 1.2	0.8±1.3	6	1	Yes	First	Any
Berdahl et al., 2017	53	6.8	19.7±1.5	12.9 ±2.1	1±0	2± 0	1±0	18	2	No	Second	Any
Ferguson et al., 2017	115	5.49	20.00 ±6.95	14.51 ±2.79	0.7	1.41± 1.04	0.71	24	1	Yes	First	Pseudoexfoliative
Gonnerman et al., 2017	25	7.8	21.3±4.1	0. 13.5 ±5	0.72	2.0± 0.9	1.28±1.17	12	2	Yes	Second	Primary, pseudoexfoliative
Kurji et al., 2017	34	3.87	17.47 ±4.87	13.6 ±3.4	0.32±0.59	2.15± 1.21	1.83±1.2	6	2	yes	First	Primary, pseudoexfoliative

* IOP = intraocular pressure.

Table 4: Distribution of clinical features for first generation studies by type of analysis

Type of analysis	Baseline feature	Comparator 1	Comparator 2	Proportion of baseline feature in comparator 1 (%)	Proportion of baseline feature in comparator 2 (%)
Number of iStents–reduction in IOP	Phacoemulsification status	One iStent	Two iStents	iStent alone: 45/999 (4.5%)	iStent alone: 90/287 (31.4%)
Number of iStents–preoperative IOP	Phacoemulsification status	One iStent	Two iStents	iStent alone: 45/999 (4.5%)	iStent alone: 90/240 (37.5%)
Number of iStents–postoperative IOP	Phacoemulsification status	One iStent	Two iStents	iStent alone: 45/882 (5.1%)	iStent alone: 90/240 (37.5%)
Number of iStents–reduction in medications	Phacoemulsification status	One iStent	Two iStents	iStent alone: 45/999 (4.5%)	iStent alone: 90/287 (31.4%)
Number of iStents–preoperative medications	Phacoemulsification status	One iStent	Two iStents	iStent alone: 45/999 (4.5%)	iStent alone: 90/336 (26.8%)
Number of iStents–postoperative medications	Phacoemulsification status	One iStent	Two iStents	iStent alone: 45/999 (4.5%)	iStent alone: 90/336 (26.8%)
Number of iStents–reduction in IOP	Phacoemulsification status	One iStent	Three iStents	iStent alone: 45/999 (4.5%)	iStent alone: 38/63 (60.3%)
Number of iStents–preoperative IOP	Phacoemulsification status	One iStent	Three iStents	iStent alone: 45/999 (4.5%)	iStent alone: 38/63 (60.3%)
Number of iStents–postoperative IOP	Phacoemulsification status	One iStent	Three iStents	iStent alone: 45/882 (5.1%)	iStent alone: 38/63 (60.3%)
Number of iStents–reduction in medications	Phacoemulsification status	One iStent	Three iStents	iStent alone: 45/999 (4.5%)	iStent alone: 38/63 (60.3%)
Number of iStents–preoperative medications	Phacoemulsification status	One iStent	Three iStents	iStent alone: 45/999 (4.5%)	iStent alone: 38/63 (60.3%)

Contd...



Efficacy and Adverse Event Profile of the iStent and iStent Inject Trabecular Micro-Bypass for Open-Angle Glaucoma

Contd...

Type of analysis	Baseline feature	Comparator 1	Comparator 2	Proportion of baseline feature in comparator 1 (%)	Proportion of baseline feature in comparator 2 (%)
Number of iStents – postoperative medications	Phacoemulsification status	One iStent	Three iStents	iStent alone: 45/999 (4.5%)	iStent alone: 38/63 (60.3%)
Number of iStents – reduction in IOP	Phacoemulsification status	Two iStents	Three iStents	iStent alone: 90/287 (31.4%)	iStent alone: 38/63 (60.3%)
Number of iStents – preoperative IOP	Phacoemulsification status	Two iStents	Three iStents	iStent alone: 90/240 (37.5%)	iStent alone: 38/63 (60.3%)
Number of iStents – postoperative IOP	Phacoemulsification status	Two iStents	Three iStents	iStent alone: 90/240 (37.5%)	iStent alone: 38/63 (60.3%)
Number of iStents – reduction in medications	Phacoemulsification status	Two iStents	Three iStents	iStent alone: 90/287 (31.4%)	iStent alone: 38/63 (60.3%)
Number of iStents – preoperative medications	Phacoemulsification status	Two iStents	Three iStents	iStent alone: 90/336 (26.8%)	iStent alone: 38/63 (60.3%)
Number of iStents – postoperative medications	Phacoemulsification status	Two iStents	Three iStents	iStent alone: 90/336 (26.8%)	iStent alone: 38/63 (60.3%)
Phacoemulsification status – IOP reduction	Number of iStents	iStent alone	Phaco-iStent	One iStent: 45/173 (26.0%)	One iStent: 901/1123 (80.2%)
Phacoemulsification status – preoperative IOP	Number of iStents	iStent alone	Phaco-iStent	One iStent: 45/173 (26.0%)	One iStent: 901/1076 (83.7%)
Phacoemulsification status – postoperative IOP	Number of iStents	iStent alone	Phaco-iStent	One iStent: 45/173 (26.0%)	One iStent: 784/959 (81.8%)
Phacoemulsification status – reduction in medications	Number of iStents	iStent alone	Phaco-iStent	One iStent: 45/173 (26.0%)	One iStent: 901/1123 (80.2%)
Phacoemulsification status – preoperative medications	Number of iStents	iStent alone	Phaco-iStent	One iStent: 45/173 (26.0%)	One iStent: 901/1172 (76.9%)
Phacoemulsification status – postoperative medications	Number of iStents	iStent alone	Phaco-iStent	One iStent: 45/173 (26.0%)	One iStent: 901/1172 (76.9%)

IOP = intraocular pressure.

Table 5A: Efficacy outcomes of one versus two first generation iStent implantation

Outcome	One iStent			Two iStents			Meta-analysis			
	Mean	Standard deviation	Number of eyes	Mean	Standard deviation	Number of eyes	Weighted mean difference	95% CI – lower bound	95% CI – upper bound	p-value
IOP reduction	4.67	2.18	999	6.03	4.66	355	-1.36	-1.86	-0.86	p <0.001
Preoperative IOP	19.72	3.06	999	21.07	3.66	240	-1.35	-1.85	-0.85	p <0.0
Postoperative IOP	14.80	1.25	882	13.78	1.62	240	1.02	0.80	1.24	p <0.001
Reduction in medications	0.97	0.46	999	1.20	0.51	287	-0.23	-0.30	-0.16	p <0.001
Preoperative medications	1.62	0.48	999	2.21	0.48	336	-0.59	-0.65	-0.53	p <0.001
Postoperative medications	0.67	0.34	999	0.95	0.64	336	-0.28	-0.35	-0.21	p <0.001

*IOP = Intraocular pressure. CI = Confidence interval

Table 5B: Efficacy outcomes of one versus three first generation iStent implantation

Outcome	One iStent			Three iStents			Meta-Analysis			
	Mean	Standard deviation	Number of eyes	Mean	Standard deviation	Number of eyes	Weighted mean difference	95%CI –Lower bound	95%CI –Upper bound	p-value
IOP reduction	4.67	2.18	999	9.33	6.23	63	-4.66	-6.20	-3.12	p <0.001
Preoperative IOP	19.72	3.06	867	22.52	4.50	63	-2.80	-3.93	-1.67	p <0.001
Postoperative IOP	14.80	1.25	882	13.23	1.80	63	1.57	1.12	2.02	p <0.001
Reduction in medications	0.97	0.46	999	1.74	0.53	63	-0.77	-0.90	-0.64	p <0.001
Preoperative medications	1.62	0.48	999	1.94	0.75	63	-0.32	-0.51	-0.13	p <0.001
Postoperative medications	0.67	0.34	999	0.21	0.22	63	0.46	0.40	0.52	p <0.001

*IOP = Intraocular pressure. CI = Confidence interval. n/a = Not available. Note: red text denotes endpoints that substantially differed from those of the original analysis.

Table 5C: Efficacy outcomes of two versus three first generation iStent implantation

Outcome	Two iStents			Three iStents			Meta-Analysis			
	Mean	Standard deviation	Number of eyes	Mean	Standard deviation	Number of eyes	Weighted mean difference	95%CI –Lower bound	95%CI –Upper bound	p-value
IOP reduction	6.03	4.66	287	9.33	6.23	63	-3.30	-4.93	-1.67	p <0.001
Preoperative IOP	21.07	3.66	240	22.52	4.50	63	-1.45	-2.65	-0.25	p = 0.02
Postoperative IOP	13.78	1.62	240	13.23	1.80	63	0.55	0.06	1.04	p = 0.03
Reduction in medications	1.20	0.51	287	1.74	0.53	63	-0.54	-0.68	-0.40	p <0.001
Preoperative medications	2.21	0.48	336	1.94	0.75	63	0.27	0.08	0.46	p = 0.006
Postoperative medications	0.95	0.64	336	0.21	0.22	63	0.74	0.65	0.83	p <0.001

*IOP = Intraocular pressure. CI = Confidence interval. n/a = Not available. Note: Red text denotes endpoints that substantially differed from those of the original analysis.

preoperative IOP [WMD = -2.80 mm Hg, 95% CI = (-3.93 mm Hg, -1.67 mm Hg), p <0.001] and lower postoperative IOP [WMD = 1.57 mm Hg, 95% CI = (1.12 mm Hg, 2.02 mm Hg), p <0.001] following three stents relative to one. There was a greater IOP reduction [WMD = -3.30 mm Hg, 95% CI = (-4.93 mm Hg, -1.67 mm Hg), p <0.001], higher preoperative IOP [WMD = -1.45 mm Hg, 95% CI = (-2.65 mm Hg, -0.25 mm Hg), p = 0.02] and a lower postoperative IOP [WMD = 0.55 mm Hg, 95% CI = (0.06 mm Hg, 1.04 mm Hg), p = 0.03] after three stents relative to two.

For the number of hypotensive medication classes, there was a greater reduction in medication classes following two iStents relative to one [WMD = -0.23, 95% CI = (-0.30, -0.16), p <0.001]. There was a significantly greater number of medication classes in two stent patients compared to one both preoperatively [WMD = -0.59, 95% CI = (-0.65, -0.53), p <0.001] and postoperatively [WMD = -0.28, 95% CI = (-0.35, -0.21), p <0.001]. Comparing between one and three stents, there was a significantly higher number of medication classes [WMD = -0.32, 95% CI = (-0.51, -0.13), p <0.001] in the three stent cohort preoperatively, as well

as a greater reduction in medication class number [WMD = -0.77, 95% CI = (-0.90, -0.64), p <0.001]. Postoperatively, the three stent group had a significantly lower medication class count [WMD = 0.46, 95% CI = (0.40, 0.52), p <0.001]. There was a greater reduction in medication classes [WMD = -0.54, 95% CI = (-0.68, -0.40), p <0.001], lower preoperative [WMD = 0.27, 95% CI = (0.08, 0.46), p = 0.006] and lower postoperative medication class count [WMD = 0.74, 95% CI = (0.65, 0.83), p <0.001] following three stents relative to two.

Phacoemulsification Status–First Generation

Next, studies were categorized by whether phacoemulsification was performed, irrespective of the number of first-generation iStents (Table 6A, Figs 3A and B). Data revealed that the iStent alone group produced a significantly more pronounced reduction in IOP than the phaco-iStent cohort [WMD = -7.44 mm Hg, 95% CI = (-7.82 mm Hg, -7.06 mm Hg), p <0.001]. The iStent alone group also had a significantly greater preoperative IOP than the phaco-iStent cohort [WMD = -5.72 mm Hg, 95% CI =

Table 6A: First Generation iStent - Efficacy Outcomes of Phaco-iStent versus iStent Implantation Alone

Outcome	Phaco-istent			Istent implantation alone			Meta-analysis			P-value
	Mean	Standard deviation	Number of eyes	Mean	Standard deviation	Number of eyes	Weighted mean difference	95% CI -Lower bound	95% CI -Upper bound	
IOP reduction	4.20	1.82	1123	11.64	2.47	173	-7.44	-7.82	-7.06	p <0.001
Preoperative IOP	19.27	2.78	1076	24.99	0.88	173	-5.72	-5.93	-5.51	p <0.001
Postoperative IOP	14.64	1.21	959	13.22	1.72	173	1.42	1.15	1.69	p <0.001
Reduction in medications	0.99	0.49	1123	1.33	0.46	173	-0.34	-0.41	-0.27	p <0.001
Preoperative medications	1.62	0.60	1172	1.87	0.44	173	-0.25	-0.32	-0.18	p <0.001
Postoperative medications	0.73	0.36	1172	0.55	0.87	173	0.18	0.05	0.31	p = 0.007

*IOP = Intraocular pressure. CI = Confidence interval. Note: Red text denotes endpoints that substantially differed from those of the original analysis.

(-5.93 mm Hg, -5.51 mm Hg), $p < 0.001$). Nonetheless, the iStent alone cohort had a lower postoperative IOP relative to the phaco-iStent cohort [WMD = 1.42 mm Hg, 95% CI = (1.15 mm Hg, 1.69 mm Hg), $p < 0.001$].

Preoperatively, patients receiving combined phaco-iStent were taking significantly fewer medication classes relative to the iStent alone group [WMD = -0.25 mm Hg, 95% CI = (-0.32 mm Hg, -0.18 mm Hg), $p < 0.001$]. There was a significantly greater reduction in medication class number following iStent alone [WMD = -0.34 mm Hg, 95% CI = (-0.41 mm Hg, -0.27 mm Hg), $p < 0.001$] along with a significantly lower postoperative medication class number in the iStent alone arm relative to phaco-iStent [WMD = 0.18 mm Hg, 95% CI = (0.05 mm Hg, 0.31 mm Hg), $p = 0.007$].

The combination of phacoemulsification and a first generation iStent was also compared to phacoemulsification alone (Table 6B, Figs 4A and B). This comparison only included studies that contained both a phaco-iStent arm and a phacoemulsification alone arm. For this analysis,

there was a significantly greater IOP reduction [WMD = 1.68 mm Hg, 95% CI = (1.11 mm Hg, 2.25 mm Hg), $p < 0.001$] and a higher preoperative IOP [WMD = 2.15 mm Hg, 95% CI = (1.35 mm Hg, 2.95 mm Hg), $p < 0.001$] following phaco-iStent relative to phacoemulsification alone. However, there was no significant difference between comparators for postoperative IOP ($p = 0.07$). Phaco-iStent resulted in a significantly more pronounced reduction in medication class number [WMD = 0.80 mm Hg, 95% CI = (0.75 mm Hg, 0.85 mm Hg), $p < 0.001$] and lower postoperative number of medication classes [WMD = -0.69 mm Hg, 95% CI = (-0.78 mm Hg, -0.60 mm Hg), $p < 0.001$] relative to phacoemulsification alone. Preoperatively, there was no significant difference between comparators ($p = 0.78$).

Phacoemulsification Status—Second Generation

For the second generation iStent *inject*, studies reporting on iStent alone had a significantly greater IOP reduction [WMD = -1.47 mm Hg, 95% CI = (-1.88 mm Hg,

Table 6B: First Generation iStent—Efficacy Outcomes of Phaco-iStent versus Phacoemulsification Alone

Outcome	Phaco-istent			Phacoemulsification alone			Meta-analysis			P-value
	Mean	Standard deviation	Number of eyes	Mean	Standard deviation	Number of eyes	Weighted mean difference	95% CI -Lower bound	95% CI -Upper bound	
IOP reduction	6.30	3.10	199	4.62	3.47	319	1.68	1.11	2.25	p <0.001
Preoperative IOP	22.44	4.24	199	20.29	4.93	319	2.15	1.35	2.95	p <0.001
Postoperative IOP	15.23	1.53	82	14.84	1.80	196	0.39	-0.03	0.81	p = 0.07
Reduction in medications	1.40	0.21	199	0.60	0.36	319	0.80	0.75	0.85	p <0.001
Preoperative medications	1.72	0.47	199	1.71	0.25	319	0.01	-0.06	0.08	p = 0.78
Postoperative medications	0.38	0.36	199	1.07	0.63	319	-0.69	-0.78	-0.60	p <0.001

*IOP = Intraocular pressure. CI = Confidence interval. Note: Red text denotes endpoints that substantially differed from those of the original analysis.




Fig. 3A: First generation phaco-iStent versus iStent alone-IOP




Fig. 3B: First generation phaco-iStent versus iStent alone—number of medication classes




Fig. 4A: First generation phaco-iStent versus phacoemulsification alone-IOP




Fig. 4B: First generation phaco-iStent versus phacoemulsification alone—number of medication classes

-1.06 mm Hg), $p < 0.001$] and a greater preoperative IOP [WMD = -0.79 mm Hg, 95% CI = (-1.54 mm Hg, -0.04 mm Hg), $p = 0.04$] compared to studies reporting on phaco-iStent (Table 7, Fig. 5A). Postoperatively, the phaco-iStent cohort had a significantly higher IOP relative to iStent alone [WMD = 0.81 mm Hg, 95% CI = (0.13 mm Hg, 1.49 mm Hg), $p < 0.001$]. There was a significantly greater reduction in medication classes [WMD = -0.22, 95% CI = (-0.28, -0.16), $p < 0.001$], higher number of preoperative medication classes [WMD = 0.20, 95% CI = (0.04, 0.36), $p = 0.01$] and a lower number of postoperative medication classes [WMD = 0.24, 95% CI = (0.02, 0.46), $p = 0.03$] following iStent alone relative to phaco-iStent (Fig. 5B).

Adverse Event Analysis

Overall, a total of 261 out of 1159 eyes (22.5%) that received iStent implantation sustained some type of adverse event (Table 8). In order from most to least common, the

following adverse events were reported: IOP elevation or spike (reported in 12 of 27 papers; 44.4%), stent blockage or obstruction (8/27; 29.6%), stent malposition (7/27; 25.9%), hyphema (6/27; 22.2%), progression of cataract (3/27; 11.1%), blood reflux (3/27; 11.1%), corneal event (3/27; 11.1%), early postoperative event (2/27; 7.4%), stent not visible (2/27; 7.4%), formation of peripheral anterior synechiae (2/27; 7.4%), need for additional surgery (2/27, 7.4%), hypotony (1/27; 3.7%), posterior capsular opacification (1/27; 3.7%), replacement applicator (1/27; 3.7%), patients soreness/discomfort (1/27; 3.7%), transient visual acuity loss (1/27; 3.7%), intraoperative hemorrhage (1/27; 3.7%) and subconjunctival hemorrhage (1/27, 3.7%). Most studies reported either stable or improved visual acuity at last follow-up.

DISCUSSION

The efficacy and adverse event profile of the iStent device have been explored in a variety of different settings. To evaluate the efficacy and adverse events following iStent






Fig. 5A: Second generation phaco-iStent versus iStent alone–IOP




Fig. 5B: Second generation phaco-iStent versus iStent alone–number of medication classes

implantation based on the consolidation of all peer-reviewed research on the iStent, the present meta-analysis was undertaken.

In a recent meta-analysis by Malvankar-Mehta et al., the efficacy of the iStent without adjunctive phacoemulsification was analyzed in 248 patients from five studies.⁴⁰ Meta-analysis revealed a significant reduction in IOP after implantation of one [standardized mean difference (SMD) = -1.68, 95% CI = (-2.7, -0.61)], two [SMD = -1.88, 95% CI = (-2.2, -1.56)] and three iStents [SMD = -2, 95% CI = (-2.62, -1.38)]. Glaucoma medication class number was reduced by a mean of 1.2 bottles after one iStent implant, 1.45 bottles after two iStents and one bottle after three iStents.

Another meta-analysis by the same team aimed to investigate the reduction of IOP after phaco-iStent compared to phacoemulsification alone.⁴¹ A total of 396 patients from 10 studies received phaco-iStent and 1768 patients from 26 studies received phacoemulsification alone. Phaco-iStent produced a significantly greater

reduction in IOP relative to cataract extraction alone [SMD = -0.46, 95%CI = (-0.87, -0.06)]. Relative to phacoemulsification alone, phaco-iStent demonstrated a statistically significantly greater reduction in glaucoma medication class number [SMD = -0.65, 95% CI = (-1.18, -0.12)]. Relative to the two studies by Malvankar-Mehta and colleagues, 20 of our 28 included peer reviewed articles have not been reported in previous meta-analyses.^{40,41}

The greater IOP reduction with multiple iStents compared to one has been documented in previous laboratory studies and was also confirmed by the findings of the present meta-analysis.⁴² For instance, both postoperative IOP and IOP reduction were significantly improved in the two-stent comparator relative to one. We hypothesize that a selection bias may have influenced these findings, as the higher initial IOP or more severe disease seen in the two-stent comparator may have contributed to the greater IOP reduction following stent implantation. For patients with high preoperative IOP (average of 22.5 mm Hg), three stents provided a more pronounced level of

Table 7: Second generation iStent - efficacy outcomes of phaco-iStent versus iStent implantation alone

Outcome	Phaco-iStent			iStent implantation Alone			Meta-analysis			
	Mean	Standard deviation	Number of eyes	Mean	Standard deviation	Number of eyes	Weighted mean difference	95% CI –Lower bound	95% CI –Upper bound	p-value
IOP reduction	8.52	1.14	45	9.99	2.14	324	-1.47	-1.88	-1.06	p <0.001
Preoperative IOP	23.39	2.39	45	24.18	2.53	324	-0.79	-1.54	-0.04	p = 0.04
Postoperative IOP	14.94	2.28	45	14.13	1.29	324	0.81	0.13	1.49	p = 0.02
Reduction in medications	0.84	0.20	45	1.06	0.16	142	-0.22	-0.28	-0.16	p <0.001
Preoperative medications	1.69	0.49	45	1.49	0.64	324	0.20	0.04	0.36	p = 0.01
Postoperative medications	0.84	0.69	45	0.60	0.58	142	0.24	0.02	0.46	p = 0.03

*IOP = Intraocular pressure. CI = Confidence interval.

Table 8: Safety endpoints of included trials

<i>Study</i>	<i>Number of eyes</i>	<i>#Complications</i>	<i>Adverse event 1</i>	<i>Adverse event 2</i>	<i>Adverse event 3</i>	<i>Adverse event 4</i>	<i>Visual acuity change</i>
Samuelson et al., 2011	111	37	Anticipated early postoperative event	Stent obstruction	Posterior capsular opacification	Stent malposition	97% BCVA improvement
Fea et al., 2014	94	3	IOP elevation	Soreness/discomfort	Stent not visible	n/a	Five people experienced decrease
Buchacra et al., 2011	8	17	HypHEMA	IOP elevation	Corneal edema	n/a	No significant change
Ahmed et al., 2014	39	7	Hypotony	Progression of cataract	Transient visual acuity loss	n/a	CDVA maintained in most eyes
Voskanyan et al., 2014	88	18	IOP elevation	Stent obstruction	Progression of cataract	Stent not visible	Slight improvement
Vandewalle et al., 2009	9	10	IOP elevation	Stent malposition	Corneal Erosion	Blood reflux	Stable/improved
Fea, 2010	12	n/a	n/a	n/a	n/a	n/a	n/a
Belovay et al., 2012	28	n/a	Stent blockage	HypHEMA	Stent malposition	IOP elevation	Stable/improved
2nd study arm	25	n/a	Stent blockage	HypHEMA	Stent Malposition	IOP elevation	Stable/improved
Patel et al., 2013	44	1	HypHEMA	n/a	n/a	n/a	Mean improved
Arriola-villalobos et al., 2012	19	12	Stent malposition	Stent blockage	Replacement applicator	IOP elevation	Significantly improved
Arriola-villalobos et al., 2013	20	10	Stent malposition	Stent blockage	IOP elevation	n/a	Significantly improved
Fernandez-barrientos et al., 2010	17	n/a	Stent malposition	n/a	n/a	n/a	n/a
Spiegel et al., 2009	42	22	Stent blockage	Stent malposition	IOP elevation	Cataract surgery Complication	Significantly improved
Wang et al., 2015	96	0	n/a	n/a	n/a	n/a	n/a
Klamann et al., 2015	32	32	Blood reflux	n/a	n/a	n/a	No decrease
Khan et al., 2015	49	26	Peripheral anterior synechiae formation	IOP spike	Early postoperative interventions	HypHEMA	n/a
Seibold et al., 2016	64	n/a	n/a	n/a	n/a	n/a	Significant improvement
Gallardo et al., 2016	134	0	n/a	n/a	n/a	n/a	83% of eyes achieved a BCVA of 20/40 or better after surgery relative to 20% preoperatively
Ferguson et al., 2016	350	n/a	IOP spike	n/a	n/a	n/a	n/a
Lindstrom et al.	57	1	Progression of cataract	n/a	n/a	n/a	Stable
El wardani et al.	31	n/a	n/a	n/a	n/a	n/a	n/a
2nd study arm	22	n/a	n/a	n/a	n/a	n/a	n/a

Contd...

Efficacy and Adverse Event Profile of the iStent and iStent Inject Trabecular Micro-Bypass for Open-Angle Glaucoma

Contd...

Study	Number of eyes	#Complications	Adverse event 1	Adverse event 2	Adverse event 3	Adverse event 4	Visual acuity change
Katz et al.	37	0	n/a	n/a	n/a	n/a	76% of eyes achieved a BCVA of 20/40 or better after surgery relative to 68% Preoperatively
2nd study arm	41	0	n/a	n/a	n/a	n/a	66% of eyes achieved a BCVA of 20/40 or better after surgery relative to 61% Preoperatively
3rd study arm	38	0	n/a	n/a	n/a	n/a	80% of eyes achieved a BCVA of 20/40 or better after surgery relative to 73% preoperatively
Shiba et al., 2017	12	Hyphema	Peripheral anterior synechiae	Occlusion by iris	lop spike	n/a	n/a
Berdahl et al, 2017	n/a	n/a	n/a	n/a	n/a	n/a	Stable
Ferguson et al., 2017	8	lop spike	Need for additional surgery	n/a	n/a	n/a	n/a
Gonnermann et al., 2017	29	Reflux bleeding	Trabulectomy	n/a	n/a	n/a	n/a
Kurji et al., 2017	3	Blocked istent	n/a	n/a	n/a	n/a	Approximate 2 line gain on snellen chart

* BCVA = Best corrected visual acuity; CDVA = Corrected distance visual acuity; IOP = Intraocular pressure.

IOP reduction (9.3 mm Hg) relative to one or two stents. However, interpretations of the three-stent data should be made with caution, as data from only 63 eyes existed for this comparison.

Regardless of the number of implanted iStents, the cohort that underwent first-generation iStent implantation alone saw a more pronounced IOP reduction and lower postoperative IOP than the phaco-iStent group. However, this comparison considers two different patient populations, namely (1) patients receiving iStent alone, who normally do not have cataracts and are receiving the device specifically for IOP reduction, and (2) patients undergoing combined phacoemulsification and iStent, who are receiving the treatment for both their cataracts and an elevated IOP. As such, the finding of a higher preoperative IOP in the iStent alone group may have influenced the difference in IOP reduction between comparators. Even though some included studies contained both patients who received phaco-iStent and iStent alone, subgroup analysis analyzing the differences in outcomes between these two groups was never performed in

individual studies.^{15,18} As such, the conclusions derived from comparing phaco-iStent versus iStent alone have not been previously established.

Analysis of phaco-iStent compared to phacoemulsification alone revealed that there was a greater IOP reduction following phaco-iStent relative to phacoemulsification alone. This aligns with the findings of Malvankar-Mehta et al., who also showed that there was a significantly greater IOP reduction following phaco-iStent relative to phacoemulsification alone [SMD = -0.46, 95% CI = (0.87, -0.06)].⁴¹ Despite the similarity, it is important to note that uncontrolled, one-armed studies examining the efficacy of phacoemulsification alone were included in the previous analysis but were excluded in the present article.⁴¹ Instead, we limited our analysis of phaco-iStent versus phacoemulsification only to the studies that had a phaco-iStent arm and a phacoemulsification only comparator, thus resulting in a more controlled analysis. Beyond analysis of IOP, both meta-analyses concluded that phaco-iStent was statistically superior relative to phacoemulsification alone in the reduction of medication class number pre- to post-operatively.

The adverse event analysis revealed that fewer than 25% of eyes carried some type of adverse event postoperatively, most of which were not serious nor visually threatening. This compares favorably with the postoperative adverse event rates of both trabeculectomy and the Baerveldt glaucoma implant.⁴³ However, due to differential reporting of adverse events between individual studies, caution should be used when interpreting these findings. In our cohort, IOP elevation, stent blockage or obstruction, stent malposition and hyphema were the most common adverse events following iStent implantation.

Beyond the efficacy and adverse event profile, the cost-effectiveness of the iStent relative to topical glaucoma medications has been studied by Iordanous and colleagues.⁴⁴ Following implantation of two iStents, the authors analyzed cost differences at 6 years postoperatively. At 6 years, the iStent was \$20.77 more expensive relative to monodrug therapy but was cheaper by \$1272.55 compared to bidrug treatment and \$2124.71 versus tridrug therapy. The authors concluded that the iStent may offer a modest cost saving when compared to glaucoma medications.

Given that past meta-analyses included lower numbers of eyes receiving iStent implantation (first article: 5 studies, $n = 248$; second article: 10 studies, $n = 396$), the present work (28 studies, $n = 1767$) represents the largest quantitative synthesis of efficacy and adverse event data for the iStent device.^{40,41} The large statistical power provided by such a high sample size allowed us to conduct certain analyses that were novel to the published literature; for example, an analysis comparing phaco-iStent to iStent alone. We only included published articles, thus ensuring that the rigors of peer-review were met for each included study.

Limitations of the analysis include the fact that there was no restriction of studies based on design. As such, baseline values for included endpoints were significantly different between comparator arms. As shown in Table 4, the relevant clinical features were often not balanced between groups. As noted by Kaplowitz et al., variation in study design and implementation such as length of follow-up, etiology of disease and baseline clinical indicators may account for the high degree of heterogeneity upon meta-analysis.⁴⁵ Further, since some articles did not include sociodemographic and clinical characteristics of their study cohorts (e.g. surgeon experience), it is uncertain whether there was a balance of these factors between comparator arms. For instance, there

is variable reporting of surgeon experience in the literature: two articles^{19,20} noted that the study surgeon was in an early stage in the learning curve, one noted that the data incorporate the surgeon learning curve,³ and another hypothesized how the learning curve influenced the greater number of adverse events in an initial set of patients.²² Two studies reported that their surgeons were experienced,^{24,30} while another found no significant difference in outcomes between initial and late procedures.²⁸ Another limitation was that the lack of available studies prevented us from performing a robust meta-analysis for some endpoints, such as IOP reduction following three stents, where there was only 63 included patients. Limited reporting of adverse event severity across studies prevented us from analyzing severity in the adverse event analysis. Studies were variable in how they handled medication washout before stent implantation, which made it impossible to analyze the effect of preoperative medications on baseline IOP. Given that data was extracted from study cohorts, conclusions should be limited to the level of the cohort.

CONCLUSION AND CLINICAL SIGNIFICANCE

The following meta-analysis has shown that there may be differences in treatment response for the iStent due to varying parameters, including the number of iStents and phaco-iStent compared to either iStent alone or phacoemulsification alone. In our analysis, two stents delivered a greater response in terms of IOP reduction relative to one and iStent alone had a significantly greater IOP reduction compared to phaco-iStent. Combined phaco-iStent was statistically superior relative to phacoemulsification alone in the reduction of IOP and medication classes pre- to post-operatively. Future research should determine whether similar conclusions are reached following meta-analysis in a more controlled environment.

ETHICAL APPROVAL

This article does not contain any studies with human participants or animals performed by any of the authors. As such, there was no informed consent process needed for this study.

AUTHORSHIP CONTRIBUTIONS

- *Conception and design of study:* M.P., X.C.M., I.I.K.A.
- *Acquisition of data:* M.P., X.C.M.
- *Analysis and interpretation of data:* M.P., X.C.M., H.S., I.I.K.A.

- Drafting and revising article: M.P., X.C.M., H.S., I.I.K.A.
- Final approval of the version to be submitted: M.P., X.C.M., H.S., I.I.K.A.

REFERENCES

1. Cook C, Foster P. Epidemiology of glaucoma: what's new? *Can J Ophthalmol*2012;47(3):223-226.
2. Bressler, Susan B.; Quigley, Harry A.; Schein, Oliver D. *Vision* January 1, 2007. Baltimore: Johns Hopkins Health; 2007.
3. Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. *Ophthalmology*2011;118:459-467.
4. Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. *Curr Opin Ophthalmol* 2004; 15:102-106.
5. Craven ER, Katz LJ, Wells JM, Giamporcaro JE. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. *J Cataract Refract Surg*2012;38:1339-1345.
6. Budenz DL, Barton K, Feuer WJ, Schiffman J, Costa VP, Godfrey DG Buys YM, Ahmed Baerveldt Comparison Study Group. Treatment outcomes in the Ahmed Baerveldt comparison study after 1 year follow-up. *Ophthalmology*2011;118:443-452.
7. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL, on behalf of the Tube Versus Trabeculectomy Study Group. Three-year follow-up of the Tube Versus Trabeculectomy Study. *Am J Ophthalmol*2009;148:670-684.
8. Saheb H, Ahmed IIK. Micro-invasive glaucoma surgery: current perspectives and future directions. *Curr Opin Ophthalmol*2012;23:96-104.
9. Lynn SC. FDA approves first glaucoma stent for use with cataract surgery. FDA Press Announcements [Internet]. 2012 Jun 2 [cited 2016 May 4]. Available from <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309667.htm>.
10. Nichamin LD. Glaukos iStent® Trabecular Micro-Bypass. *Middle East Afr J Ophthalmol*2009;16(3):138-140.
11. Fea AM, Belda JI, Rekas M, Junemann A, Chang L, Pablo L Voskanyan L, Katz LJ. Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma. *Clin Ophthalmol*2014;8:875-882.
12. Buchacra O, Duch S, Milla E, Stirbu O. One-year analysis of the iStent trabecular microbypass in secondary glaucoma. *Clin Ophthalmol*2011;5:321-326.
13. Ahmed IIK, Katz LJ, Chang DF, Donnenfeld ED, Solomon KD, Voskanyan L, Samuelson TW. Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma. *J Cataract Refract Surg*2014;40:1295-1300.
14. Voskanyan L, Garcia-Feijoo J, Belda JI, Fea A, Junemann A, Baudouin C. Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial. *Adv Ther*2014;31:189-201.
15. Vandewalle E, Zeyen T, Stalmans I. The iStent® trabecular micro-bypass stent: a case series. *Bull Soc Belge Ophthalmol*2009;311:23-29.
16. Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma: randomized double-masked clinical trial. *J Cataract Refract Surg*2010;36:407-412.
17. Belovay GW, Naqi A, Chan BJ, Rateb M, Ahmed IIK. Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma. *J Cataract Refract Surg*2012;38:1911-1917.
18. Patel I, de Klerk TA, Au L. Manchester iStent study: early results from a prospective UK case series. *Clin Exp Ophthalmol*2013;41:648-652.
19. Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, Fernandez-Perez C, Garcia-Sanchez J, Garcia-Feijoo J. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. *Br J Ophthalmol*2012;96:645-649.
20. Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, Garcia-Vidal SE, Fernandez-Perez C, Garcia-Sanchez J, Garcia-Feijoo J. Mid-term evaluation of the new Glaukos iStent with phacoemulsification in coexistent open-angle glaucoma or ocular hypertension and cataract. *Br J Ophthalmol*2013;97:1250-1255.
21. Fernandez-Barrientos Y, Garcia-Feijoo J, Martinez-de-la-Casa JM, Pablo LE, Fernandez-Perez C, Garcia-Sanchez J. Fluorophotometric study of the effect of the Glaukos trabecular microbypass stent on aqueous humor dynamics. *Invest Ophthalmol Vis Sci*2010;51(7):3327-3332.
22. Spiegel D, Wetzel W, Neuhann T, Sturmer J, Hoeh H, Garcia-Feijoo J, Martinez-De-La-Casa JM, Garcia-Sanchez J. Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. *Eur J Ophthalmol*2009;19:393-398.
23. Wang Q, Harasymowycz P. Short-term intraocular pressure elevations after combined phacoemulsification and implantation of two trabecular micro-bypass stents: prednisolone versus loteprednol. *J Ophthalmol*2015;2015(2015):1-5.
24. Klamann MKJ, Gonnermann J, Pahlitzsch M, Maier AKB, Jousen AM, Torun N, Bertelmann E. iStent inject in phakic open angle glaucoma. *Graefes Arch Clin Exp Ophthalmol*2015;253:941-947.
25. Khan M, Saheb H, Neelakantan A, Fellman R, Vest Z, Harasymowycz P, Ahmed II. Efficacy and safety of combined cataract surgery with 2 trabecular microbypass stents versus ab interno trabeculotomy. *J Cataract Refract Surg*2015;41:1716-1724.
26. Seibold LK, Gamett KM, Kennedy JB, Mulvahill MJ, Kroehl ME, SooHoo JR, Pantcheva MB, Kahook MY. Outcomes after combined phacoemulsification and trabecular microbypass stent implantation in controlled open-angle glaucoma. *J Cataract Refract Surg*2016;42:1332-1338.
27. Gallardo MJ, Supnet RA, Giamporcaro JE, Hornbeak DM. Outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic patient population. *Clin Ophthalmol*2016;10:1931-1937.
28. Ferguson TJ, Berdahl JP, Schweitzer JA, Sudhagoni RG. Clinical evaluation of a trabecular microbypass stent with phacoemulsification in patients with open-angle glaucoma and cataract. *Clin Ophthalmol*2016;10:1767-1773.

29. Lindstrom R, Lewis R, Hornbeak DM, Voskanyan L, Giamporcaro JE, Hovanesian J, Sarkisian S. Outcomes following implantation of two second-generation trabecular micro-bypass stents in patients with open-angle glaucoma on one medication: 18-month follow-up. *Adv Ther*2016;33:2082-2090.
30. El Wardani M, Bergin C, Achache F, Sharkawi E. Evaluating the trabecular micro-bypass stent combined with phacoemulsification compared to phacoemulsification alone. *Klin Monatsbl Augenheilkd*2015;232(4):442-445.
31. Katz LJ, Erb C, Carceller A, Guillamet, Fea AM, Voskanyan L, Wells JM, Giamporcaro JE. Prospective, randomized study of one, two, or three trabecular micro-bypass stents in open-angle glaucoma subjects on topical hypotensive medication. *Clin Ophthalmol*2015;9:2313-2320.
32. Shiba D, Hosoda S, Yaguchi S, Ozeki N, Yuki K, Tsubota K. Safety and efficacy of two trabecular micro-bypass stents as the sole procedure in Japanese patients with medically uncontrolled primary open-angle glaucoma: a pilot case series. *J Ophthalmol*2017;2017:9605461.
33. Zheng CX, Moster MR, Gogte P, Dai Y, Manzi RS, Waisbourd M. Implantation of trabecular micro-bypass stent using a novel "landing strip" technique. *Int J Ophthalmol*2017;10(5):738-741.
34. Berdahl J, Voskanyan L, Myers JS, Hornbeak DM, Giamporcaro JE, Katz LJ, Samuelson TW. Implantation of two second-generation trabecular micro-bypass stents and topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 18-month follow-up. *Clin Exp Ophthalmol*2017;45:797-802.
35. Ferguson TJ, Swan R, Ibach M, Schweitzer J, Sudhagoni R, Berdahl J. Trabecular microbypass stent implantation with cataract extraction in pseudoexfoliation glaucoma. *J Cataract Refract Surg*2017;43:622-626.
36. Gonnermann J, Bertelmann E, Pahlitzsch M, Maier-Wenzel AKB, Torun N, Klamann MKJ. Contralateral eye comparison study in MICS and MIGS: Trabectome® vs. iStent inject®. *Graefes Arch Clin Exp Ophthalmol*2017;255:359-365.
37. Kurji K, Rudinsky CJ, Rayat JS, Arora S, Sandhu S, Damji KF, Dorey MW. Phaco-trabectome versus phaco-iStent in patients with open-angle glaucoma. *Can J Ophthalmol*2017;52(1):99-106.
38. Higgins JP, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0. London: Cochrane Collaboration; c2011 March 2011.
39. National Institute for Health and Care Excellence. *Quality Assessment for Case Series* [Internet]. 2003 [cited 2017 Mar 3]. Available from: <https://www.nice.org.uk/guidance/cg3/resources/appendix-4-quality-of-case-series-form2>.
40. Malvankar-Mehta MS, Chen YN, Iordanous Y, Wang WW, Costella J, Hutnik CML. iStent as a solo procedure for glaucoma patients: a systematic review and meta-analysis. *PLoS One*2015;10(5):e0128146.
41. Malvankar-Mehta MS, Iordanous Y, Chen YN. iStent with phacoemulsification versus phacoemulsification alone for patients with glaucoma and cataract: a meta-analysis. *PLoS One*2015;10(7):e0131770.
42. Bahler CK, Smedley GT, Zhou J, Johnson DH. Trabecular bypass stents decrease intraocular pressure in cultured human anterior segments. *Am J Ophthalmol*2004;138(6):988-994.
43. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Postoperative complications in the tube versus trabeculectomy (TVT) study during five years of follow-up. *Am J Ophthalmol*2012;153(5):804-814.
44. Iordanous Y, Kent JS, Hutnik CML, Malvankar-Mehta MS. Projected cost comparison of Trabectome, iStent, and endoscopic cyclophotocoagulation versus glaucoma medication in the Ontario Health Insurance Plan. *J Glaucoma*2014;23:e112-118.
45. Kaplowitz K, Bussel II, Honkanen R, Schuman JS, Loewen NA. Review and meta-analysis of ab-interno trabeculectomy outcomes. *Br J Ophthalmol* 2016;100(5):594-600.